
The Controlled High zzso zzso Multiple zzso Study zzso tested whether zzso beta la zzso treatment would benefit patients who had experienced a first acute zzso event involving the zzso zzso brain zzso or spinal cord, and who displayed zzso brain signal abnormalities that have previously predicted a high likelihood of future zzso zzso The study zzso zzso patients into an zzso and a zzso zzso both groups received intravenous zzso 1 zzso followed by prednisone 1 zzso for 11 zzso The zzso group demonstrated a zzso reduction in the zzso cumulative probability of developing clinically zzso multiple sclerosis zzso ratio zzso zzso confidence zzso zzso to zzso P zzso zzso At 18 months, treatment with zzso was associated with a significant reduction of new zzso zzso zzso enhanced zzso and zzso zzso zzso Among zzso patients, zzso had developed a new zzso zzso signal zzso by the zzso month after study zzso Treatment benefit was observed irrespective of the qualifying zzso The findings of this study support the efficacy of zzso therapy in significantly reducing the zzso likelihood of future zzso events and worsening of the brain zzso in patients with a first acute zzso zzso zzso 

